modern insulin analogues are a convenient new approach or tool to glycaemic control , associated with low number of hypoglycaemia and favourable weight change .
a1chieve , a multinational , 24-week , non - interventional study , assessed the safety and effectiveness of insulin analogues in people with t2 dm ( n = 66,726 ) in routine clinical care .
please refer to editorial titled : the a1chieve study : mapping the ibn battuta trail .
the patient characteristics for the entire cohort divided as insulin - nave and insulin users is shown in the table 1 .
the majority of patients ( 48.8% ) started on or were switched to biphasic insulin aspart .
other groups were insulin detemir ( n = 54 ) , insulin aspart ( n = 8) , basal insulin plus insulin aspart ( n = 8) and other insulin combinations ( n = 33 ) . overall demographic data after 24 weeks of treatment , overall hypoglycaemia reduced from 20.8 events / patient - year to 4.3 events / patient - year in insulin user group whereas hypoglycaemic events increased from 0.3 events / patient - year to 2.0 events / patient - year in insulin nave group . however , this hypoglycaemia incidence in insulin naive group at 24 weeks was still lower than that observed in insulin users at baseline .
blood pressure and lipid profile improved in the total cohort , but the findings were limited by number of observations .
quality of life also improved after 24 weeks of treatment [ tables 2 and 3 ] .
all parameters of glycaemic control improved from baseline to study end in the total cohort [ table 4 ] .
overall efficacy data of the total cohort , 98 patients started on biphasic insulin aspart  ogld , of which 69 ( 70.4% ) were insulin nave and 29 ( 29.6% ) were insulin users .
after 24 weeks of treatment , hypoglycaemic events reduced from 21.5 events / patient - year to 1.2 events / patient - year in insulin user group whereas hypoglycaemia increased from 0.4 events / patient - year to 2.4 events / patient - year in insulin nave group .
quality of life also improved at the end of the study [ tables 5 and 6 ] .
biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] .
biphasic insulin aspartoral glucose - lowering drug efficacy data of the total cohort , 8 patients started on basal + insulin aspart  ogld , of which 1 ( 12.5% ) was insulin nave and 7 ( 87.5% ) were insulin users .
after 24 weeks , hypoglycaemic events reduced from 26.0 events / patient - year to 9.3 events / patient - year in insulin user group [ tables 8 and 9 ] .
basal+insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were basal + insulin aspart  oglds for insulin - user group [ table 10 ] .
basal+insulin aspartoral glucose - lowering drug efficacy data of the total cohort , 54 patients started on insulin detemir  ogld , of which 46 ( 85.2% ) were insulin nave and 8 ( 14.8% ) were insulin users .
after 24 weeks of starting or switching to insulin detemir , hypoglycaemia reduced from 11.4 events / patient - year to 0.0 events / patient - year in insulin user group whereas hypoglycaemic events increased from 0.0 to 1.1 events / patient - year in insulin nave group .
an improvement in quality of life was also observed at the end of the study [ tables 11 and 12 ] .
insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for insulin - nave group whereas mean hba1c and fpg values improved for insulin user group [ table 13 ] .
insulin detemiroral glucose - lowering drug efficacy data of the total cohort , 8 patients started on insulin aspart  ogld , of which 5 ( 62.5% ) were insulin nave and 3 ( 37.5% ) were insulin users .
after 24 weeks of treatment , hypoglycaemic events reduced from 65.0 events / patient - year to 6.5 events / patient - year in insulin user group [ table 14 ] .
insulin aspartoral glucose - lowering drug safety data mean fpg values improved from baseline to study end in those who started on or were switched to insulin aspart  oglds for insulin - nave group [ table 16 ] .
of the total cohort , 98 patients started on biphasic insulin aspart  ogld , of which 69 ( 70.4% ) were insulin nave and 29 ( 29.6% ) were insulin users .
after 24 weeks of treatment , hypoglycaemic events reduced from 21.5 events / patient - year to 1.2 events / patient - year in insulin user group whereas hypoglycaemia increased from 0.4 events / patient - year to 2.4 events / patient - year in insulin nave group .
quality of life also improved at the end of the study [ tables 5 and 6 ] .
biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] .
of the total cohort , 8 patients started on basal + insulin aspart  ogld , of which 1 ( 12.5% ) was insulin nave and 7 ( 87.5% ) were insulin users .
after 24 weeks , hypoglycaemic events reduced from 26.0 events / patient - year to 9.3 events / patient - year in insulin user group [ tables 8 and 9 ] .
basal+insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were basal + insulin aspart  oglds for insulin - user group [ table 10 ] .
of the total cohort , 54 patients started on insulin detemir  ogld , of which 46 ( 85.2% ) were insulin nave and 8 ( 14.8% ) were insulin users .
after 24 weeks of starting or switching to insulin detemir , hypoglycaemia reduced from 11.4 events / patient - year to 0.0 events / patient - year in insulin user group whereas hypoglycaemic events increased from 0.0 to 1.1 events / patient - year in insulin nave group .
an improvement in quality of life was also observed at the end of the study [ tables 11 and 12 ] .
insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for insulin - nave group whereas mean hba1c and fpg values improved for insulin user group [ table 13 ] .
of the total cohort , 8 patients started on insulin aspart  ogld , of which 5 ( 62.5% ) were insulin nave and 3 ( 37.5% ) were insulin users .
after 24 weeks of treatment , hypoglycaemic events reduced from 65.0 events / patient - year to 6.5 events / patient - year in insulin user group [ table 14 ] .
insulin aspartoral glucose - lowering drug safety data mean fpg values improved from baseline to study end in those who started on or were switched to insulin aspart  oglds for insulin - nave group [ table 16 ] .
our study reports improved glycaemic control following 24 weeks of treatment with any of the insulin analogues ( biphasic insulin aspart ; basal + insulin aspart ; insulin detemir ; insulin aspart ) with or without ogld .
overall , body weight increased in insulin nave population and decreased in insulin users . though the findings are limited by number of patients , still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in in agadir , morocco .
 background : a1chieve , a multicentric ( 28 countries ) , 24-week , non - interventional study evaluated the safety and effectiveness of insulin detemir , biphasic insulin aspart and insulin aspart in people with t2 dm ( n = 66,726 ) in routine clinical care across four continents.materials and methods : data was collected at baseline , at 12 weeks and at 24 weeks . this short communication presents the results for patients enrolled from agadir , morocco.results:a total of 201 patients were enrolled in the study . 
 four different insulin analogue regimens were used in the study . 
 study patients had started on or were switched to biphasic insulin aspart ( n = 98 ) , insulin detemir ( n = 54 ) , insulin aspart ( n = 8) , basal insulin plus insulin aspart ( n = 8) and other insulin combinations ( n = 33 ) . at baseline glycaemic control was poor for both insulin nave ( mean hba1c : 10.7% ) and insulin user ( mean hba1c : 9.1% ) groups . 
 after 24 weeks of treatment , both groups showed improvement in hba1c ( insulin nave : 2.7% , insulin users : 1.3% ) . 
 no major hypoglycaemia was observed at 24 weeks . 
 sadrs were reported in 1.5% of insulin users.conclusion:starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia . 
I
M
R
Biphasic insulin aspart  OGLD
Basal + insulin aspart  OGLD
Insulin detemir  OGLD
Insulin aspart  OGLD
C